In Federal Circuit brief the court's former chief judge, the ex-USPTO head and the influential Republican Senator make plain why they believe the EDTX anti anti-suit injunction should stand
As political wrangling and potential for commercial fallout mounted, the two Korean battery suppliers reached an eleventh-hour settlement deal yesterday
An affiliate of the South Korean company recently sold over 100 assets to an NPE, while other parts of the portfolio are reportedly being shopped by brokers Read more
After letter from Senators Leahy and Tillis telling President Biden to pick up the pace of appointments, Hill source tells IAM that IP needs to be seen as a tier one priority Read more
After seeing her work recognised by the IPO, the company's assistant chief IP counsel Sandra Nowak spoke with IAM on why some parts of the market are still playing catch-up Read more
World’s largest trade pact is not a show-stopper when it comes to IP, but it will bring changes to ASEAN and clouds US ability to set regional agenda Read more
A year after a major capital infusion and a change of leadership, the firm has notched some notable settlements in the US and laid the groundwork for new assertion campaigns Read more
A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models Read more
The countdown of this year's IAM Market Makers - our annual ranking of the 40 most influential players in the global IP market - begins today with places 40 to 21 Read more
In the first quarter the Swedish telecoms giant was the most targeted patent owner at the PTAB while data shows new district court cases increased in Q1 Read more
While the US and other countries are seeking out alternatives to the small pool of providers, the numbers point to familiar faces dominating parts of the landscape Read more
US cases brought by PanOptis and Sisvel were dismissed earlier this month, adding to evidence that auto company might have signed up to wireless pool Read more
Former agency head doubles down on his message that the US needs a national innovation policy and that the country’s policymakers need to wake up to SEPs Read more
The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions Read more
In an exclusive interview, the influential US legislator reveals his tier-one IP priorities and explains why Tiffany Cunningham looks like the right CAFC pick Read more
After letter from Senators Leahy and Tillis telling President Biden to pick up the pace of appointments, Hill source tells IAM that IP needs to be seen as a tier one priority Read more
Former agency head doubles down on his message that the US needs a national innovation policy and that the country’s policymakers need to wake up to SEPs Read more
In an exclusive interview, the influential US legislator reveals his tier-one IP priorities and explains why Tiffany Cunningham looks like the right CAFC pick Read more
Latest initiative by financial services giant could rise in value to $1 billion and is focused on companies that are beyond their first funding round Read more
Financial figures disclosed as supplement to IPO prospectus, in latest sign regulators are wary of waving through companies facing major overseas IP litigation Read more
The long read: In an exclusive interview, the German company's James Ryan and Julie Anne Gillespie talk about their once-in-a-career experience of working on a project that will help change the world Read more
Announcing the creation of SPIF - a non-partisan, open standard, human readable solution for uniquely identifying patent assets that is consistent with existing formats Read more
Announcing its annual results, the NPE also reports significant gains from its investments in life sciences businesses previously associated with UK fund manager Neil Woodford Read more
US cases brought by PanOptis and Sisvel were dismissed earlier this month, adding to evidence that auto company might have signed up to wireless pool Read more
AST's buying programme was back again in 2020 and while it generated close to $3 million, the total was down on the previous year and the 2016 record Read more
Technologist and VC funder Alex Eleftheriadis warns that VVC is on a slippery slope to the same kind of fractured licensing landscape as HEVC Read more
US cases brought by PanOptis and Sisvel were dismissed earlier this month, adding to evidence that auto company might have signed up to wireless pool Read more
Former agency head doubles down on his message that the US needs a national innovation policy and that the country’s policymakers need to wake up to SEPs Read more
The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions Read more
The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions Read more
In the first quarter the Swedish telecoms giant was the most targeted patent owner at the PTAB while data shows new district court cases increased in Q1 Read more
The long read: There is growing evidence that patent litigants are turning to ex parte reexaminations to bolster their PTAB strategies. Cozen O’Connor’s Jeffrey Townes and Hongling Zou analyse why older tools deserve a second look and explore how to get best value from them Read more
The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions Read more
Announcing its annual results, the NPE also reports significant gains from its investments in life sciences businesses previously associated with UK fund manager Neil Woodford Read more
Technologist and VC funder Alex Eleftheriadis warns that VVC is on a slippery slope to the same kind of fractured licensing landscape as HEVC Read more
Announcing the creation of SPIF - a non-partisan, open standard, human readable solution for uniquely identifying patent assets that is consistent with existing formats Read more
After letter from Senators Leahy and Tillis telling President Biden to pick up the pace of appointments, Hill source tells IAM that IP needs to be seen as a tier one priority Read more
After IAM broke news of possible sale last year Canadian tech giant has confirmed it is in exclusive negotiations with a “North American” bidder for a part of its 38,000 asset stockpile Read more
The Canadian tech giant has built a licensing operation that brings in more than $300 million annually, but those gains have failed to shift shareholder sentiment Read more